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Abstract  
A high throughput screen allowed the identification of N-hydroxyimide inhibitors of ERCC1-
XPF endonuclease activity with micromolar potency, but they showed undesirable selectivity 
profiles against FEN-1. A scaffold hop to a hydroxypyrimidinone template gave compounds 
with similar potency but allowed selectivity to be switched in favour of ERCC1-XPF over 
FEN-1. Further exploration of the structure-activity relationships around this chemotype gave 
sub-micromolar inhibitors with >10-fold selectivity for ERCC1-XPF over FEN-1. 
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Platinum-based chemotherapeutics such as cisplatin result in several forms of DNA damage, 
however their effectiveness can be limited by efficient DNA repair processes. The ERCC1-
XPF complex is essential for one such process, nucleotide excision repair (NER), and there is 
evidence that it is a good therapeutic target for potential intervention in a range of cancers,1,2 
where inhibition of ERCC1-XPF could enhance the effectiveness of chemotherapeutic 
agents.  
 
A high-throughput screen using a fluorescence-based in vitro biochemical assay3 allowed the 
identification of hit compounds 1 and 2 as inhibitors of the endonuclease activity of ERCC1-
XPF, with micromolar potency and good ligand efficiency (Figure 1). Despite their flat 
structures and the N-hydroxyimide motif which was considered undesirable, they did not 
show DNA intercalation of our assay substrate and we noted the similarity of the structure to 
known flap endonuclease 1 (FEN-1) inhibitors4 and the natural product flutimide,5,6 an 
inhibitor of influenza endonuclease. We therefore sought to explore whether it was possible 
to gain additional potency and selectivity for ERCC1-XPF over other nucleases including 
FEN-1 from this starting point. The testing of initial analogues showed that the N-hydroxy 
group was essential for inhibitory activity since replacement of the N-OH by either N-H or N-
methyl led to complete loss of activity. The mode of inhibition of FEN-1 by N-
hydroxyimides has been proposed to involve chelation of metal ions at the endonuclease 
active site;4  the enzymatic activity of ERCC1-XPF is also metal-dependent and the presence 
of Mn2+ is required for substrate turnover in the biochemical assay, so it was our hypothesis 
that the hits are also able to inhibit ERCC1-XPF through binding to a metal ion at the 
endonuclease active site. 
 
Figure 1. Initial hit compounds 
 
 
Synthesis and testing of known FEN-1 inhibitors 3-64 (Table 1) showed that they could also 
inhibit ERCC1-XPF at micromolar levels, although due to their high potency against FEN-1 
they were highly selective for this target versus ERCC1-XPF. In order to monitor the 
selectivity of inhibitors during the optimization process, we employed counter screen assays 
against the non-structure specific nuclease DNase I as well as FEN-1. The phenyl analogue 7 
showed lower potency than the thiophene 5, although the addition of aniline (8) or 
pyrrolidine (9) substituents allowed some potency to be regained. The acetamido- substituted 
positional variants (examples 10-12) all showed similar potency against ERCC1-XPF but 
encouragingly suggested that it might be possible to tune the selectivity of these inhibitors 
towards ERCC1-XPF inhibition and away from FEN-1 (11, 12), although it still remained in 
favour of FEN-1. The N-substituted analogue 13 was consistent with 6 in suggesting that 
substitution at this position is not tolerated, and 14 showed good potency for its size although 
was still more potent against FEN-1. 
 
 
Table 1. Initial activity and selectivity data based around known N-hydroxyimide FEN-1 inhibitors and their 
analogues 
 
 
 
 
 
 
 
 
Compound Core R1 R2 R3 R4 ERCC1-XPF IC50/ µM 
FEN-1 
IC50/ µM 
DNase I 
IC50/ µM 
3 A H 
 
H - 1.5 0.057 >100 
4 B H 
 
H - 1.8 0.003 >100 
5 C H H H - 3.9 0.009 >100 
ERCC1-XPF IC50 = 30 M
Ligand efficiency = 0.38 
FEN-1 IC50 = 0.3 M 
1 2
ERCC1-XPF IC50 = 12 M
Ligand efficiency = 0.39 
FEN-1 IC50 = 0.7 M 
D ECA B
6 C H H 
 
- 80.4 0.68 >100 
7 D H H H H 18.1 0.30 >100 
8 D H 
 
H H 3.9 0.23 30.2 
9 D H 
 
H H 9.1 1.1 27.9 
10 D H H 
 
H 6.1 0.038 >100 
11 D H 
 
H H 6.4 2.1 >100 
12 D 
 
H H H 6.6 2.0 87 
13 D H H H Me 96.2 2.1 >100 
14 E H  H - 1.5 0.63 >100 
 
 
In order to advance the series with the aim of improving potency and selectivity we 
investigated a scaffold hop to introduce additional vectors for exploration and avoid the 
requirement for the N-O bond, which was considered a liability from an ADMET 
perspective. The scaffold chosen was hydroxypyrimidinone (Figure 2), which is known to be 
able to bind metal ions (typically Mg2+) in a similar way to the N-hydroxyimide and is 
present in the blockbuster HIV integrase drug raltegravir,7 inhibitors of HCV polymerase8,9 
and RNase H.10 
 
 
Figure 2. Scaffold hop to hydroxypyrimidinone motif11 
 
Compounds containing this scaffold were synthesized and tested, and gratifyingly initial 
examples showed comparable inhibition of ERCC1-XPF to the N-hydroxyimides (Table 2). 
With either thiophene or phenyl as the R1 substituent, the carboxylic acids 15 and 17 showed 
IC50 values around 3 µM and approximately 4-fold selectivity for ERCC1-XPF over FEN-1. 
Their methyl ester analogues 16 and 18 were found to have weaker potency than the 
corresponding carboxylic acids and modifications around the metal-binding motif, through 
R
A B C
either N-methylation (19) or O-methylation (20), led to losses in potency. These initial 
examples represented a promising start with respect to potency against ERCC1-XPF and 
achieving selectivity against FEN-1 and DNase I. 
 
 
Table 2. Initial activity data from scaffold hop 
 
 
 
 
 
 
 
 
Compound Core R1 R2 ERCC1-XPF IC50/ µM 
FEN-1 
IC50/ µMa 
DNase I 
IC50/ µMa 
15 A 
 
H 2.9 10.4 >100 
16 A 
 
Me 27.3 10.1 >100 
17 A  H 3.9 16.4 >100 
18 A  Me 16.4 53.4 >100 
19 B 
 
H 48.8 88.9 >100 
20 C 
 
H >100 nt nt 
a nt = not tested. 
 
The carboxylic acids and esters are highly polar and carry limited vectors for additional 
substitution for exploring potency and selectivity gains, so amides instead of acids were 
investigated (Table 3). It was found that a range of amides was well tolerated and potency 
gains to the sub-micromolar level against ERCC1-XPF were achieved, although the SAR 
appeared relatively flat in this region. The primary carboxamide 21, methyl amide 22, small 
lipohilic alkyl chains (23, 26, 27) and appended polar groups (24, 28, 32) were all well 
tolerated, but the tertiary amide 25 was less potent.  Aryl and heteroaryl groups also showed 
similar potency (29, 31). They showed variable FEN-1 selectivity but in the best case, with 
the primary carboxamide 21, greater than 20-fold selectivity was observed. 
 
 
Table 3. Activity data from variations at amide position 
Compound NR1R2 ERCC1-XPF IC50/ µM 
FEN-1 
IC50/ µM 
DNase I 
IC50/ µMa 
21  1.0 23.3 >100 
22 
 0.6 12.0 67.6 
23  2.7 4.2 >100 
24  0.7 4.0 >100 
25 
 
4.6 13.7 nt 
26  0.6 1.3 >100 
27 
 
0.5 3.5 nt 
28 
 
0.8 5.0 62.6 
29  0.8 10.5 nt 
30 
 
4.2 2.1 >100 
31 
 
0.7 8.6 >100 
32 
 
1.0 4.1 58.9 
a nt = not tested. 
 
Although the potency gains from introducing the amides were modest relative to the 
carboxylic acids, a better balance in compound properties and ADMET profiles was obtained 
(Table 4). While the carboxylic acids typically showed log D values of less than zero and 
were not permeable in the PAMPA assay, modifying the amide substituent enabled tuning of 
the log D of the compounds which led to corresponding improvements in the permeability. 
They also displayed good stability in both mouse and human liver microsomes. 
 
 
Table 4. Measured in vitro ADMET profiles for selected compounds 
 
Compound Log D Cytotox Hep-G2 v-50/ µM 
MLM 
t1/2/ mins 
HLM 
t1/2/ mins 
PAMPA 
Papp/ nms-1 
21 -0.4 >10 150 139 7 
22 0.5 >10 >400 181 31 
26 2.1 >10 >400 >400 97 
 
With the isopentyl group in place as the amide substituent, changes at the pyrimidinone 2-
position were explored (Table 5). In this region it was found that pendant groups could be 
added to a phenyl ring without significant losses in potency, such as basic groups in 33 and 
34, but the introduction of saturated ring systems led to losses in potency (examples 35-38).  
 
 
Table 5. Activity data from variations at 2-position 
Compound R1 ERCC1-XPF IC50/ µM 
FEN-1 
IC50/ µM 
33 
 
0.8 38.1 
34  1.7 71.3 
35 
 
6.3 >100 
36 
 
8.4 >100 
37 
 
25.3 >100 
38 
 
6.9 >100 
 
 
In order to address the possibility that the compounds could be inhibiting enzyme activity in a 
non-specific manner, such as through general metal chelation, it was important to test the 
compounds in biophysical assays to confirm binding to ERCC1-XPF. Compound 22 was 
profiled by surface plasmon resonance (SPR), where it displayed a KD of 4 µM with fast 
binding kinetics (Figure 3) and also in a thermal shift assay, where it showed a ΔTm of 4°C. 
 
 
 
 
 
Figure 3. SPR sensorgram for compound 22 
 
Compound 22 was tested (up to 10 µM) in cell based assays using A375 melanoma cells to 
assess effects on DNA repair. Three assays were used to measure the following parameters: 
direct nucleotide excision repair (NER) using a recombinant GFP reporter assay,3 
potentiation of cisplatin induced cell death and a high content imaging assay measuring levels 
of γH2AX foci, a marker of DNA repair.12 We did not observe any inhibition of repair of 
damaged GFP DNA by compound 22 in the NER assay and in the cell viability assay run 
over 5 days, the compound alone did not cause toxicity but neither did it enhance the cell 
death seen with cisplatin (dose response range of cisplatin of 0.1 to 3 µM).  Similarly, we did 
not observe a delay in the repair of DNA damage caused by cisplatin by addition of 
compound 22 in the γH2AX foci assay (data not shown). In view of the cell activity shown 
by a compound with similar biochemical potency,12 it is somewhat surprising that 22 showed 
no activity in these assays and there are a number of reasons why this might be the case. 
Despite acceptable physical and ADMET properties, it might be that insufficient compound 
concentration at the target was achieved, or alternatively that inhibition of ERCC1-XPF 
activity in these cells is not sufficient to stop DNA repair. Unlike the catechol series,12 no cell 
toxicity was observed with compound alone for the hydroxypyrimidinones, which could 
suggest that the cellular effects seen with the catechol series are due to inhibiting targets and 
pathways in addition to ERCC1-XPF. Further studies to measure target engagement in the 
cell and probe on- versus off-target effects for both the catechols and hydroxypyrimidinones 
would be required to confirm this, but it might be the case that a combination approach will 
be required to achieve efficacy in a therapeutic.    
 
In summary, we have shown that compounds with the N-hydroxyimide metal-binding 
chemotype are able to inhibit the activity of ERCC1-XPF, although they are also highly 
potent against FEN-1. Promisingly, performing a scaffold hop to a hydroxypyrimidinone 
template allowed sub-micromolar inhibitors of ERCC1-XPF to be obtained with >10-fold 
selectivity over the other nucleases FEN-1 and DNase I; the inhibitors were also shown to 
bind to ERCC1-XPF in SPR and thermal shift assays. Further work to understand the binding 
mode of these compounds, for example if a crystal structure could be obtained, might reveal 
additional opportunities to drive improvements in enzyme affinity and cell activity and 
advance their utility as probes for ERCC1-XPF biology. 
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